

doi 10.18699/vjgb-25-47

Methylation index of the *DLK1* and *MKRN3* genes in precocious puberty

E.A. Sazhenova ¹✉, O.Yu. Vasilyeva ¹, D.A. Fedotov ¹, M.B. Kankanam Pathirana ², A.D. Lobanov ³,
A.Yu. Sambyalova ⁴, E.E. Khramova ⁴, L.V. Rychkova ⁴, S.A. Vasilyev ^{1, 2}, I.N. Lebedev ^{1, 3}

¹ Scientific Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

² Tomsk State University, Tomsk, Russia

³ Siberian State Medical University, Tomsk, Russia

⁴ Scientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia

✉ elena.sazhenova@medgenetics.ru

Abstract. Precocious puberty (PP, OMIM 176400, 615346) is an autosomal dominant disorder caused by the premature reactivation of the hypothalamic-pituitary-gonadal axis. Genetic, epigenetic, and environmental factors play a decisive role in determining the timing of puberty. In recent years, genetic variants in the *KISS1*, *KISS1R*, *MKRN3*, and *DLK1* genes have been identified as genetic causes of PP. The *MKRN3* and *DLK1* genes are imprinted, and therefore epigenetic modifications, such as DNA methylation, which alter the expression of these genes, can also contribute to the development of PP. The aim of this study is to determine the methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes in girls with a clinical presentation of PP. The methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes was analyzed in a group of 45 girls (age 7.2 ± 1.9 years) with a clinical presentation of PP and a normal karyotype using targeted massive parallel sequencing after sodium bisulfite treatment of DNA. The control group consisted of girls without PP ($n = 15$, age 7.9 ± 1.6 years). No significant age differences were observed between the groups ($p > 0.8$). Analysis of the methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes revealed no significant differences between patients with PP and the control group. However, in the group of patients with isolated adrenarche, an increased methylation index of the imprinting center of the *MKRN3* gene was observed (72 ± 7.84 vs 56.92 ± 9.44 %, $p = 0.005$). In the group of patients with central PP, 3.8 % of patients showed a decreased methylation index of the imprinting center of the *DLK1* gene, and 11.5 % of probands had a decreased methylation index of the imprinting center of the *MKRN3* gene. Thus, this study demonstrates that not only genetic variants but also alterations in the methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes can contribute to the development of PP.

Key words: precocious puberty; gonadotropin-releasing hormone (GnRH); hypothalamic-pituitary-gonadal axis (HPG); genomic imprinting; *DLK1*; *MKRN3*

For citation: Sazhenova E.A., Vasilyeva O.Yu., Fedotov D.A., Kankanam Pathirana M.B., Lobanov A.D., Sambyalova A.Yu., Khramova E.E., Rychkova L.V., Vasilyev S.A., Lebedev I.N. Methylation index of the *DLK1* and *MKRN3* genes in precocious puberty. *Vavilovskii Zhurnal Genetiki i Selekcii* = *Vavilov J Genet Breed*. 2025;29(3):440-447. doi 10.18699/vjgb-25-47

Funding. The study was supported by the Russian Science Foundation, grant number 23-25-00359.

Индекс метилирования генов *DLK1* и *MKRN3* при преждевременном половом созревании

Е.А. Саженова ¹✉, О.Ю. Васильева ¹, Д.А. Федотов ¹, М.Б. Канканам Патиранге ², А.Д. Лобанов ³,
А.Ю. Самбялова ⁴, Е.Е. Храмова ⁴, Л.В. Рычкова ⁴, С.А. Васильев ^{1, 2}, И.Н. Лебедев ^{1, 3}

¹ Научно-исследовательский институт медицинской генетики, Томский национальный исследовательский медицинский центр Российской академии наук, Томск, Россия

² Национальный исследовательский Томский государственный университет, Томск, Россия

³ Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации, Томск, Россия

⁴ Научный центр проблем здоровья семьи и репродукции человека, Иркутск, Россия

✉ elena.sazhenova@medgenetics.ru

Аннотация. Преждевременное половое созревание (ППС, OMIM 176400, 615346) – заболевание, которое вызвано преждевременной реактивацией гипоталамо-гипофизарно-гонадной оси. В определении сроков полового созревания ведущую роль играют генетические, эпигенетические и экологические факторы. В последние годы варианты в генах *KISS1*, *KISS1R*, *MKRN3* и *DLK1* были идентифицированы как генетические причины ППС.

Гены *MKRN3* и *DLK1* являются импринтированными, в связи с чем эпигенетические модификации, такие как метилирование ДНК, изменяющее экспрессию данных генов, также могут рассматриваться в качестве причины ППС. Цель настоящего исследования – определение индекса метилирования центров импринтинга генов *DLK1* и *MKRN3* у девочек с клинической картиной ППС. Анализ индекса метилирования центров импринтинга генов *DLK1* и *MKRN3* проводили в группе из 45 девочек (возраст 7.2 ± 1.9 года) с клинической картиной ППС и нормальным кариотипом методом таргетного массового параллельного секвенирования после обработки ДНК бисульфитом натрия. Контрольная группа состояла из девочек без ППС ($n = 15$, возраст 7.9 ± 1.6 года). Различий по возрасту между группами не выявлено ($p > 0.8$). Анализ индекса метилирования центров импринтинга генов *DLK1* и *MKRN3* не показал различий между пациентами с ППС и контрольной группой. Группа пациентов с изолированным адренархе имела повышенный индекс метилирования центра импринтинга гена *MKRN3* (72 ± 7.84 против 56.92 ± 9.44 %, $p = 0.005$). В группе пациентов с центральным ППС 3.8 % пациентов имели пониженный индекс метилирования центра импринтинга гена *DLK1* и 11.5 % – гена *MKRN3*. Таким образом, показано, что не только генетические варианты, но и нарушение индекса метилирования центров импринтинга генов *DLK1* и *MKRN3* могут быть причиной ППС.

Ключевые слова: преждевременное половое созревание; гонадотропин-рилизинг-гормон (ГнРГ); гипоталамо-гипофизарно-гонадная ось (ГПГ); геномный импринтинг; *DLK1*; *MKRN3*

Introduction

Adolescence is one of the key stages of personality development, characterized by complex changes in the neuroendocrine system and other biological processes that lead to physical and sexual maturation. The appearance of secondary sexual characteristics before the age of 8 in girls and 9 in boys is defined as precocious puberty (PP), with an incidence of approximately 3.7 cases per 10,000 individuals. Recently, the prevalence of this condition has been increasing (Chebotareva et al., 2022; Alghamdi, 2023). According to the International Classification of Diseases (ICD-10), PP is categorized into E22.8 (conditions of pituitary hyperfunction, central precocious puberty) and E30.9 (unspecified disorder of puberty, including isolated thelarche and isolated adrenarche).

The timing of the onset of puberty is significantly influenced by the child's gender, race, genetic predisposition, environmental factors, diet, and socioeconomic status (Sazhenova et al., 2023). For example, obesity and exogenous hormone intake can have adverse effects (Peterkova et al., 2021; Micangeli et al., 2023). However, over the past decade, several genes have been identified that are part of a complex network of inhibitory, activating, and regulatory neuroendocrine factors critical for controlling the onset of puberty. These include *KISS1* (1q32.1) and its receptor *KISS1R* (*GPR54*, 19p13.3), as well as two imprinted genes that are normally expressed only from the paternal allele: *DLK1* (14q32) and *MKRN3* (15q11.2) (Roberts, Kaiser, 2020; Faienza et al., 2022). The primary mechanism of monoallelic expression of imprinted genes is allele-specific DNA methylation, which establishes differential methylation patterns on the two parental chromosomes.

DLK1 (OMIM 176290) encodes an EGF-like membrane-bound protein that belongs to the epidermal growth factor family, participates in the Notch signaling pathway, and regulates preadipocyte differentiation. It is expressed in neuroendocrine tissues, particularly in the adrenal cortex (Gomes et al., 2019; Macedo, Kaiser, 2019). The *MKRN3* gene (OMIM 603856) belongs to the makorin family and plays a role in regulating the onset of puberty by inhibiting the release of GnRH from the hypothalamus, thereby delaying the onset of puberty (Abreu et al., 2020). The *MKRN3* gene encodes a protein containing a zinc finger RING domain, which is characteristic of most E3 ubiquitin ligases involved in intracellular protein degrada-

tion via the ubiquitin-proteasome pathway. The *MKRN3* gene may interact with proteins associated with puberty, insulin signaling, RNA metabolism, and intercellular adhesion (Li C. et al., 2021).

The *DLK1* and *MKRN3* genes, like most imprinted genes, are regulated by imprinting centers. The *DLK1* gene has two imprinting centers: the germline *MEG3/DLK1*:IG-DMR and the secondary *MEG3*:TSS-DMR, which is established after fertilization. *MKRN3* is regulated by the germline imprinting center *SNURF*:TSS-DMR and is directly controlled by the somatic *MKRN3*:TSS-DMR. These imprinting centers are methylated exclusively on the paternal allele in somatic tissues, such as leukocytes and skin fibroblasts (Okac et al., 2014).

Imprinted genes are known to play a crucial role in the development of both the brain and the placenta, the organ responsible for nourishing the embryo. Disruptions in the hypothalamic-pituitary system, which regulates the endocrine activity of the brain during embryonic development, can adversely affect the formation of the fetal endocrine system (Tucci et al., 2019). The fetal pituitary gland produces hormones such as somatotrophic, follicle-stimulating, luteinizing, and thyroid-stimulating hormones, which are essential for fetal growth and the regulation of puberty. Dysfunction in the production of these hormones can lead to intrauterine growth restriction or PP after birth (Canton et al., 2021). It is possible that some cases of PP are associated with disruptions in the imprinted state of the *DLK1* and *MKRN3* genes.

The aim of this study is to determine the methylation index of the imprinted regions of the *DLK1* and *MKRN3* gene imprinting centers in girls with a clinical presentation of PP.

Material and methods

The molecular genetic analysis included 45 girls with PP and a normal karyotype, aged 7.2 ± 1.9 years. This group was divided into two subgroups: girls with hyperpituitary function (PP of central origin, ICD-10: E22.8, $n = 26$, age 7.6 ± 1.4 years) and those with unspecified PP (ICD-10: E30.1, $n = 19$, age 6.9 ± 0.8 years). The latter subgroup was further divided into girls with isolated thelarche ($n = 11$, age 7.4 ± 1.2 years) and isolated adrenarche ($n = 8$, age 6.8 ± 1.4 years). The control group consisted of girls without PP ($n = 15$, age

7.9 ± 1.6 years). No significant age differences were observed between the groups ($p > 0.8$). The patient cohort was recruited from the Scientific Center of Family Health and Human Reproduction Problems, Irkutsk. The study was conducted in accordance with the principles of the World Medical Association's Helsinki Declaration. The study protocol was approved by the bioethics committee of the Scientific Center of Family Health and Human Reproduction Problems, Irkutsk (Protocol No. 1.1, dated January 12, 2023). Informed consent for participation in the study and DNA analysis was obtained from the parents or legal guardians of all participants.

Description of patient subgroups:

- Girls with the isosexual gonadotropin-dependent form of PP, under 8 years old, exhibiting accelerated physical development (height SDS +1 or more), with their sexual development corresponding to Tanner stages 2–4, levels of pituitary gonadotropic hormones corresponding to pubertal values, and a positive buserelin test. Additionally, they have enlarged mammary glands and uterus, as confirmed by ultrasound, and their biological age does not match their chronological (passport) age.
- Girls with isolated enlargement of the mammary glands (thelarche), under 8 years old, with either accelerated or normal physical development (height SDS +1 or more), advanced sexual development corresponding to Tanner stage 2, levels of pituitary gonadotropic hormones corresponding to prepubertal values, and a negative buserelin test. Additionally, they exhibit enlarged mammary glands and uterus, which is confirmed by ultrasound.
- Girls with isolated adrenarche, under 8 years old, with either accelerated or normal physical development (height SDS +1 or more), advanced sexual development corresponding to Tanner stage 2–3, levels of pituitary gonadotropic hormones corresponding to prepubertal values, and a negative buserelin test. Additionally, they exhibit enlarged mammary glands and uterus, which is confirmed by ultrasound.

All probands underwent standard cytogenetic analysis, which showed a normal karyotype in all cases. Karyotyping was performed using a research-grade microscope Axiolmager (Carl Zeiss, Germany).

Genomic DNA was isolated from venous blood by phenol-chloroform extraction. Bisulfite modification of DNA was performed using the EZ DNA Methylation-Direct Kit (Zymo Research, USA) according to the manufacturer's protocol. During bisulfite conversion, unmethylated cytosine is modified to uracil, which is replaced by thymine during further PCR, and methylated cytosine is not modified. Methylation index analysis was performed using targeted bisulfite massive parallel sequencing.

To create libraries, specially designed oligonucleotide primers were used that allow amplification of target genome regions from bisulfite-converted DNA. Primers were selected for imprinted regions containing CpG dinucleotides of the *MEG3/DLK1*:IG-DMR and *MKRN3*:TSS-DMR imprinting centers, which control the expression of the *DLK1* and *MKRN3* genes, respectively. The UCSC genome browser (University of California, Santa Cruz), which contains information on genome sequences (GRCh38), was used to obtain the nucleotide sequence. The obtained nucleotide sequence was then used to select primers using the MethPrimer bioinformatics program

(Li L.C., Dahiya, 2002). Vector NTI Advance 11.5 was used to test the thermodynamic properties of the primers.

The imprinted *DLK1* gene is located on chromosome 14, at locus 14q32.2. Expression of this gene is regulated by the imprinting center *MEG3/DLK1*:IG-DMR, position 100,809,090–100,811,721 (GRCh38). This genomic region contains 52 CpG dinucleotides, changes in the methylation index of which can affect the expression of this gene. Expression of the imprinted *MKRN3* gene, located on chromosome 15, at locus 15q11.2, is regulated by the imprinting center *MKRN3*:TSS-DMR, position 23,561,939–23,567,348 (GRCh38). This genomic region contains 26 CpG dinucleotides, changes in the methylation index of which affect the expression of this gene (see the Table).

Amplification of target fragments was carried out using the HS-Taq PCR kit (2×) (Biolabmix, Russia) according to the manufacturer's protocol with the following PCR conditions: 95 °C for 5 min; 36 cycles: 95 °C for 20 s, 66 °C for 30 s, 72 °C for 40 s. The concentration of the target fragments was determined using a Qubit 4.0 fluorimeter (Thermo Fisher Scientific, USA). The reaction products were purified using Sephadex G50 solution (Sigma, USA). Targeted bisulfite massive parallel sequencing was performed on a MiSeq device (Illumina, USA) using a Micro kit (2x150).

The quality of the reads was evaluated using FastQC v0.11.8, after which the remaining adapter sequences and low-quality reads were trimmed using Trim-Galore. The reads were then mapped to bisulfite-converted target sequences using the bwa-meth tool (v0.2.2) with default parameters. Methylation data in the context of CpG were extracted from the resulting BAM files using the MethylDackel tool. The results were presented as the methylation index, which is the ratio of the number of cytosines to the total number of cytosines and thymines in a specific CpG site. In addition, the average methylation index was calculated along all target sites.

A limitation of the targeted bisulfite massive parallel sequencing used in this study is the impossibility of differentiating hypomethylation of the identified imprinting centers from uniparental disomy of chromosomes 14 and 15, as well as from microdeletions in these regions. Therefore, in case of detection of a decrease in the methylation index in the imprinting centers of the *DLK1* and *MKRN3* genes, real-time PCR was performed for the intergenic locus 14q32.3 and the *NIPAI* gene (15q11.2), respectively, to exclude deletion variants in these regions.

Statistical analysis was performed using the Statistica 10.0 software package (StatSoft, USA). The Mann–Whitney rank test was used to compare the methylation index between groups of samples. The differences were considered statistically significant at $p < 0.05$.

The study was conducted using the equipment of the center for collective use “Medical Genomics” of the Tomsk National Research Medical Center of the Russian Academy of Sciences.

Results

Analysis of the methylation index of 52 CpG dinucleotides of the imprinting center of the *DLK1* gene (*MEG3/DLK1*:IG-DMR) in the control group showed that three loci (*DLK1_3_520*, *DLK1_4_422*, and *DLK1_5_509*) are hypermethylated, which is atypical for imprinted genes

Sequences of the oligonucleotide primers used for analysis of the imprinting centers of the *DLK1* and *MKRN3* gene

Primer name	Primer sequence, 5' – 3'	Position in genome (GRCh38)	Length of product, bp	Number of CpG dinucleotides
<i>MEG3/DLK1:IG-DMR</i>				
D1R1	GTTGTTTTGATTTGTTAGGTT	chr100809428–100810087	659	11
D1F1	ACCTTATCCCACATAAAATA			
D1F2	ATTTTGGATTTGTAGTTGGG	chr100809940–100810497	557	13
D1R2	CCTATCTTACTCTTCTAAAAAAC			
D1F3	GATAAGGTAGGATAAGAAAAGTA	chr100810080–100810720	640	14
D1R3	CCAAAATCAATACTCAACTC			
D1F4	AGGTTTGAGTTTGAGTTATT	chr100810692–100811466	655	22
D1R4	ACAATTTAACAACAACCTTCCTC			
D1F5	GTAGTTTTAGTAGTGTAGT	chr100811196–100811815	619	13
D1R5	CTACACCTTTTAATCCAAAAA			
Total		2,387 bp		52*
<i>MKRN3:TSS-DMR</i>				
M3F1	TAGATGGGATAAAAGAAGGTAAT	chr23561945–23562513	568	22
M3R1	CCTCAAAAACATAAACCTAA			
M3F2	TTTTTTGTGTTAGGAGATGAGA	chr23562966–23563522	556	2
M3R2	CTTCTCCTTTTCATAATTACCA			
M3F3	TTAGAAAAGAAGGTATAGTTGAG	chr23562528–23563130	602	2
M3R3	ACCCATAAAATCTTAAAC			
Total		1,577 bp		25*

* Taking into account the overlap of the analyzed regions.

(Fig. 1a). When superimposing the methylation index of the control group and the group of probands with PP for these CpG dinucleotides, it is also evident that these loci have an increased methylation index and do not differ from the control group (Fig. 1a). Therefore, these loci were not included in the present study. In contrast to the *DLK1* imprinting center, only one of the 25 CpG dinucleotides (*MKRN3_3_296*) of the *MKRN3* gene imprinting center (*MKRN3:TSS-DMR*) in the control group was atypically hypermethylated (Fig. 1b). When comparing the methylation of the control group and probands with PP, an increased methylation index was also observed for this locus (Fig. 1b). Therefore, this locus was also not included in further analysis.

The average methylation index of the *DLK1* imprinting center in probands with PP was not significantly different from the control group ($51.46 \pm 9.59\%$ vs $58.44 \pm 7.15\%$, respectively, $p = 0.058$). Although a slight decrease in this index was noted, it was not statistically significant (Fig. 1a). Girls with PP were then divided into three subgroups based on their symptoms: central PP, isolated thelarche, and isolated adrenarche. Pairwise comparisons between these subgroups also failed to reveal significant differences in the methylation level of this gene (Fig. 2a): $58.44 \pm 7.15\%$ in the control group, $53.32 \pm 8.56\%$ in the group with central PP, $57.40 \pm 9.31\%$, with isolated thelarche, and $59.74 \pm 2.05\%$, with isolated adrenarche ($p > 0.05$). Comparison of the meth-

ylation index of each patient with PP and the control group revealed that only one patient with central PP showed a significant decrease in methylation (31.16% vs $58.44 \pm 7.15\%$, $p < 0.01$). Consequently, in the PP group, there is a decrease in methylation levels in the imprinting control region of the *DLK1* gene in 2.22 % (1/45) of patients, and in girls with central PP, this decrease occurs in 3.84 % (1/26) of cases.

Analysis of the methylation index of the imprinting center of the *MKRN3* gene showed no significant differences between patients with PP and the control group ($53.71 \pm 10.30\%$ vs $56.92 \pm 9.26\%$, $p = 0.71$). However, when the group with PP was divided into three subgroups (central PP, isolated thelarche, and isolated adrenarche), there was a significant increase in the methylation index in the adrenarche group compared to the control ($72.00 \pm 7.84\%$ vs $56.92 \pm 9.44\%$, $p < 0.005$) (Fig. 2b). Comparison of the methylation level of each patient with the control group revealed that three patients with central PP had reduced levels (34.09, 29.01, and 32.08 %, compared to $56.92 \pm 9.44\%$ in the control, $p < 0.01$). Therefore, 6.66 % of patients (3/45) in the PP group and 11.53 % of patients in the central PP group (3/26) had reduced methylation levels of the *MKRN3* imprinting center.

The decrease in the methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes may indicate both uniparental disomy of chromosomes 14 and 15 of maternal origin and deletions of these regions on chromosomes of pa-




Fig. 1. Methylation index of CpG dinucleotides of the imprinting centers of the *DLK1* (a) and *MKRN3* (b) genes.




Fig. 2. Pairwise comparison of the mean methylation index of the *DLK1* and *MKRN3* imprinted genes between the groups.

ternal origin. Deletion variants that included the imprinting centers of the *DLK1* and *MKRN3* genes were excluded by real-time PCR. Uniparental disomy for chromosomes 14 and 15 was not excluded. At the same time, uniparental disomy of chromosomes 14 and 15 is a very rare event (1:50,000 people for chromosome 15) (Butler, 2020).

Thus, in the present study, the analysis of the methylation index of the imprinting centers of the *DLK1* and *MKRN3* genes between patients with PP and the control group showed no significant differences between the two groups. However, the group of patients with isolated adrenarche had a significantly increased methylation index of the *MKRN3* imprinting center

(72.00 ± 7.84 % vs 56.92 ± 9.44 %, $p < 0.005$). In the group of patients with central PP, 3.8 % of patients had a decreased methylation index of the *DLK1* gene, and 11.5 %, that of the *MKRN3* gene. The presence of epimutations simultaneously in two loci was not detected in any proband.

Discussion

In recent years, there has been an increasing understanding of how epigenetic factors influence the timing of puberty. The current study found a statistically significant reduction in the methylation level of the imprinting centers for the *DLK1* and *MKRN3* genes among a group of girls with central PP. This reduction was observed in 3.84 % of patients for *DLK1*, and 11.53 %, for *MKRN3*. It is worth noting that a decrease in methylation level (hypomethylation) at the *DLK1* imprinting site has also been reported in 8.8 % of individuals with Temple syndrome (Narusawa et al., 2024), a disorder characterized by pre- and postnatal growth retardation, hypotonia, feeding difficulties, delayed motor development, joint laxity, trunk obesity, and facial dysmorphisms (e. g., broad forehead, short nose, micrognathia). In some cases, an early onset of puberty has also been reported (Kagami et al., 2019).

The core clinical features of Temple syndrome are similar to those of Russell–Silver (OMIM 180860) and Prader–Willi (OMIM 176270) syndromes (Kagami et al., 2015; Abi Habib et al., 2019). In the present study, a decrease in the methylation index of the *DLK1* gene imprinting center was found in one proband with PP, who also had obesity, pericallosal lipoma, and hypogenesis of the corpus callosum. In addition to PP and obesity, the clinical picture of the patient did not correspond to the phenotype of Temple syndrome. According to the literature, Canton et al. (2020) showed a decrease in the methylation index of the *DLK1* imprinting center in 2.5 % (3/120) of patients with PP, prenatal and postnatal growth retardation, hypotonia, and feeding difficulties. Further study of these cases revealed the presence of uniparental disomy of chromosome 14 of maternal origin in two of them.

Hypomethylation of the imprinting center of the *MKRN3* gene may be associated with dysfunction of other genes that are normally imprinted and expressed only from the paternal chromosome. These genes include *MAGEL2*, *NECDIN*, *NPAP1/C15orf2*, *SNURF-SNRPN*, *MKRN3-AS/ZNF127-AS*, *UBE3A-AS*, *IPW*, *SNORD116*, *SNORD115*, *SNORD64*, *SNORD107*, *SNORD108*, *SNORD109A*, and *SNORD109B*.

Uniparental disomy of the maternal chromosome 15 or deletion of the paternal copy of these genes can cause Prader–Willi syndrome. The clinical picture of this syndrome includes muscular hypotonia, obesity, hyperphagia, short stature, hypogonadism, and mental retardation of varying severity. Rarely, this syndrome can be accompanied by PP (Nicoara et al., 2023). Patients with hypomethylation of the imprinting center of the *MKRN3* gene, as identified in this study, had central PP, but without the clinical features of Prader–Willi syndrome. Deletion of the 15q11–q13 region was excluded in these patients. If they had uniparental disomy of this region from the mother, it would certainly lead to the clinical picture of Prader–Willi syndrome. Therefore, it seems that these patients likely only had hypomethylation of the *MKRN3* imprinting center.

An increase in the methylation index of the imprinting center of the *MKRN3* gene has also been shown in the group of

proband with isolated adrenarche. Premature adrenarche in children is not caused by premature activation of the hypothalamic-pituitary-gonadal axis, but it is associated with excessive activation of the reticular zone of the adrenal glands, which is the source of dehydroepiandrosterone (DHEA). DHEA is converted into testosterone and dihydrotestosterone in peripheral tissues. During intrauterine development, the adrenal glands start to produce DHEA, which is used to produce placental estriol. A timely increase in androgen levels is necessary for puberty, promoting growth and strengthening of bone tissue, as well as stimulating the process of red blood cell production. Moderate levels of DHEA activate the development of the prefrontal cortex in the brain, providing neuroprotective and neurotrophic effects, and regulate the function of GABA receptors, which are the main inhibitory neurotransmitters in the central nervous system.

Hypermethylation of the *MKRN3* imprinting center leads to increased expression of the gene, resulting in an increased amount of protein produced. *MKRN3* then ubiquitinates various factors to suppress the production of gonadotropin-releasing hormone 1 (*GNRH1*). Ubiquitination of the transcriptional repressor MBD3 inhibits its binding to both the *GNRH1* promoter and DNA TET2 demethylase, resulting in epigenetic silencing of *GNRH1* transcription. Additionally, *MKRN3* mediates the ubiquitination of poly(A)-binding proteins, such as PABPC1, PABPC3, and PABPC4. This reduces their binding to the poly(A) tail of target mRNA, including *GNRH1* mRNA. This affects the stability and translation of these mRNAs (Li C. et al., 2020; Fanis et al., 2022). The *MKRN3* expression is also found in the adrenal glands, although its role in activating adrenarche remains unknown.

Genome-wide, exome-wide, and methylome-wide association studies on the pathogenetic heterogeneity of PP have shown that genetic variants in the *KISS1R*, *KISS1*, *MKRN3*, and *DLK1* genes occur in approximately 10 % of sporadic cases and 27 % of familial cases. Copy number variations (7q11.23 deletions, Xp22.33 deletions, 1p31.3 duplications) are found in 4 % of patients. Epigenetic abnormalities at the imprinting centers of the *DLK1* and *MKRN3* genes are rare, as reported by Canton et al. (2020). Whole exome sequencing has also identified rare, *de novo* variants that cause loss of gene function in the dominant state. These include the *TNRC6B* (22q13.1), *AREL1* (14q24.3), *PROKR2* (20p12.3), and *LIN28B* (6q16.3) genes, although their roles in the disease process are not fully understood (Shim et al., 2022).

Methylome analysis of this pathology has shown the presence of hypomethylation in the promoter region of the *ZFP57* gene (6p22.1) (Bessa et al., 2018). *ZFP57* contains a KRAB domain, which is a transcriptional repressor, and different genetic variants of this gene have been linked to multi-locus imprinting disturbance (MLID), such as transient neonatal diabetes mellitus (OMIM 601410). This condition is accompanied by hypomethylation of several other imprinted genes, including *PLAGL1*, *GRB10*, and *PEG3* (Monteagudo-Sánchez et al., 2020; Mackay et al., 2024). The expression of the *ZFP57* gene in the hypothalamus of female rhesus macaques has been shown to increase during peripubertal development. This indicates an enhanced repression of downstream target genes of *ZFP57* (Bessa et al., 2018). The increased expression of *ZFP57* has been observed in the hypothalamus of mature

female monkeys. This indicates that this gene may play a role in suppressing the activity of transcription repressors involved in puberty, such as the Polycomb complex (Lomniczi et al., 2015).

Thus, it has been shown that not only genetic variations, but also a disruption of the methylation pattern of the imprinting regions of the *DLK1* and *MKRN3* genes, can be a cause of PP.

Conclusion

Puberty is a multifactorial process with a triggering role of genetic and epigenetic factors. In this study, no significant changes in methylation of the imprinting centers of the *DLK1* and *MKRN3* genes were shown between patients with the clinical picture of PP compared to the control group. Despite this, it was found that a group of patients with isolated adrenarche had an increased methylation index of the imprinting center of the *MKRN3* gene. Among the girls with central PP, 3.8 % had a decreased methylation index for the imprinting centers of the *DLK1* and 11.5 % of the *MKRN3* genes, and the total contribution from methylation disorders in these genes was 15.3 %. No probands had epimutations in both of these loci at the same time.

Therefore, it was demonstrated that not only genetic, but also epigenetic changes may be responsible for PP through methylation disorders in the imprinting regions of the *DLK1* and *MKRN3* genes. However, there are some limitations to the conclusions drawn, and there may be other epigenetic factors that can also influence the formation of PP, such as epimutations in other imprinted genes or mutations in the imprinting centers that control the expression of imprinted genes. Nevertheless, this study shows the epigenetic role of the imprinted genes *DLK1* and *MKRN3* in the development of PP.

References

- Abi Habib W., Brioude F., Azzi S., Rossignol S., Lingart A., Sobrier M.-L., Giabiconi É., Steunou V., Harbison M.D., Le Bouc Y., Netchine I. Transcriptional profiling at the *DLK1/MEG3* domain explains clinical overlap between imprinting disorders. *Sci Adv.* 2019;5:e9425. doi 10.1126/sciadv.aau9425
- Abreu A.P., Toro C.A., Song Y.B., Navarro V.M., Bosch M.A., Eren A., Liang J.N., Carroll R.S., Latronico A.C., Ronnekleiv O.K. *MKRN3* inhibits the reproductive axis through actions in kisspeptin-expressing neurons. *J Clin Invest.* 2020;130(8):4486-4500. doi 10.1172/JCI136564
- Alghamdi A. Precocious puberty: types, pathogenesis and updated management. *Cures.* 2023;15(10):e47485. doi 10.7759/cureus.47485
- Bessa D.S., Maschietto M., Aylwin C.F., Canton A.P.-M., Brito V.N., Macedo D.B., Cunha-Silva M., ... Netchine I., Krepischi A.C.V., Lomniczi A., Ojeda S.R., Latronico A.C. Methylome profiling of healthy and central precocious puberty girls. *Clin Epigenetics.* 2018;10:e146. doi 10.1186/s13148-018-0581-1
- Butler M.G. Imprinting disorders in humans: a review. *Curr Opin Pediatr.* 2020;32(6):719-729. doi 10.1097/MOP.0000000000000965
- Canton A.P.M., Steunou V., Sobrier M.-L., Montenegro L.R., Bessa D.S., Gomes L.G., Jorge A.A.L., Mendonça B.B., Brito V.N., Netchine I., Latronico A.C. Investigation of imprinting defects in *MKRN3* and *DLK1* in children with idiopathic central precocious puberty through specific DNA methylation analysis. *J Endocr Soc.* 2020;4(1):SUN-090.A426. doi 10.1210/jendso/bvaa046.847
- Canton A.P.M., Krepischi A.C.V., Montenegro L.R., Costa S., Rosenberg C., Steunou V., Sobrier M.L., ... Jorge A.A.L., Mendonça B.B., Netchine I., Brito V.N., Latronico A.C. Insights from the genetic characterization of central precocious puberty associated with multiple anomalies. *Hum Reprod.* 2021;36(2):506-518. doi 10.1093/humrep/deaa306
- Chebotaeva Yu.Yu., Petrov Yu.A., Rodina M.A. Some aspects of precocious puberty in preschool-age girls. *Russian Journal of Woman and Child Health.* 2022;5(3):215-222. doi 10.32364/2618-8430-2022-5-3-215-222 (in Russian)
- Faenza M.F., Urbano F., Moscioguri L.A., Chiarito M., De Santis S., Giordano P. Genetic, epigenetic and environmental influencing factors on the regulation of precocious and delayed puberty. *Front Endocrinol (Lausanne).* 2022;13:e1019468. doi 10.3389/fendo.2022.1019468
- Fanis P., Morrou M., Tomazou M., Michailidou K., Spyrou G.M., Tumba M., Skordis N., Neocleous V., Phylactou L.A. Methylation status of hypothalamic *Mkdn3* promoter across puberty. *Front Endocrinol (Lausanne).* 2022;13:e1075341. doi 10.3389/fendo.2022.1075341
- Gomes L.G., Cunha-Silva M., Crespo R.P., Ramos C.O., Montenegro L.R., Canton A., Lees M., ... Baracat E.C., Jorge A.A.L., Mendonça B.B., Brito V.N., Latronico A.C. *DLK1* is a novel link between reproduction and metabolism. *J Clin Endocrinol Metab.* 2019;104(6):2112-2120. doi 10.1210/je.2018-02010
- Kagami M., Mizuno S., Matsubara K., Nakabayashi K., Sano S., Fuke T., Fukami M., Ogata T. Epimutations of the IG-DMR and the *MEG3*-DMR at the 14q32.2 imprinted region in two patients with Silver-Russell syndrome-compatible phenotype. *Eur J Hum Genet.* 2015;23(8):1062-1067. doi 10.1038/ejhg.2014.234
- Kagami M., Yanagisawa A., Ota M., Matsuoka K., Nakamura A., Matsubara K., Nakabayashi K., Takada S., Fukami M., Ogata T. Temple syndrome in a patient with variably methylated CpGs at the primary *MEG3/DLK1*:IG-DMR and severely hypomethylated CpGs at the secondary *MEG3*:TSS-DMR. *Clin Epigenetics.* 2019;11(1):e42. doi 10.1186/s13148-019-0640-2
- Li C., Lu W., Yang L., Li Z., Zhou X., Guo R., Wang J., ... Wang W., Huang X., Li Y., Gao S., Hu R. *MKRN3* regulates the epigenetic switch of mammalian puberty via ubiquitination of *MBD3*. *Natl Sci Rev.* 2020;7(3):671-685. doi 10.1093/nsr/nwaa023
- Li C., Han T., Li Q., Zhang M., Guo R., Yang Y., Lu W., ... Zhou V., Han Z., Li H., Wang F., Hu R. *MKRN3*-mediated ubiquitination of Poly(A)-binding proteins modulates the stability and translation of *GNRH1* mRNA in mammalian puberty. *Nucleic Acids Res.* 2021;49(7):3796-3813. doi 10.1093/nar/gkab155
- Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCR. *Bioinformatics.* 2002;18(11):1427-1431. doi 10.1093/bioinformatics/18.11.1427
- Lomniczi A., Wright H., Castellano J.M., Matagne V., Toro C.A., Ramaswamy S., Plant T.M., Ojeda S.R. Epigenetic regulation of puberty via zinc finger protein-mediated transcriptional repression. *Nat Commun.* 2015;6:e10195. doi 10.1038/ncomms10195
- Macedo D.B., Kaiser U.B. *DLK1*, Notch signaling and the timing of puberty. *Semin Reprod Med.* 2019;37(4):174-181. doi 10.1055/s-0039-3400963
- Mackay D.J.G., Gazdag G., Monk D., Brioude F., Giabiconi E., Krzyzewska I.M., Kalish J.M., ... Russo S., Tannorella P., Temple K.I., Önap K., Tümer Z. Multi-locus imprinting disturbance (MLID): interim joint statement for clinical and molecular diagnosis. *Clin Epigenetics.* 2024;16:99. doi 10.1186/s13148-024-01713-y
- Micangeli G., Paparella R., Tarani F., Menghi M., Ferraguti G., Carlomagno F., Spaziani M., Pucarelli I., Greco A., Fiore M. Clinical management and therapy of precocious puberty in the Sapienza university pediatrics hospital of Rome, Italy. *Children (Basel).* 2023;10(10):e1672. doi 10.3390/children10101672
- Monteagudo-Sánchez A., Hernandez M.J.R., Simon C., Burton A., Tenorio J., Lapunzina P., Clark S., ... Kelsey G., López-Sigüero J.P., de Nancrales G.P., Torres-Padilla M.E., Monk D. The role of *ZFP57* and additional KRAB-zinc finger proteins in the maintenance of human imprinted methylation and multi-locus imprinting disturbances. *Nucleic Acids Res.* 2020;48(20):11394-11407. doi 10.1093/nar/gkaa837

- Narusawa H., Ogawa T., Yagasaki H., Nagasaki K., Urakawa T., Saito T., Soneda S., ... Naiki Y., Horikawa R., Ogata T., Fukami M., Kagami M. Comprehensive study on central precocious puberty: molecular and clinical analyses in 90 patients. *J Clin Endocrinol Metab.* 2024;26:e666. doi 10.1210/clinem/dgae666
- Nicoara D.M., Scutca A.C., Mang N., Juganaru I., Munteanu A.I., Vit-tan L., Mărginean O. Central precocious puberty in Prader-Willi syndrome: a narrative review. *Front Endocrinol (Lausanne)*. 2023; 14:e1150323. doi 10.3389/fendo.2023.1150323
- Okae H., Chiba H., Hiura H., Hamada H., Sato A., Utsunomiya T., Ki-kuchi H., Yoshida H., Tanaka A., Suyama M., Arima T. Genome-wide analysis of DNA methylation dynamics during early human development. *PLoS Genet.* 2014;10:e1004868. doi 10.1371/journal.pgen.1004868
- Peterkova V.A., Alimova I.L., Bashnina E.B., Bezlepkin O.B., Bolo-tova N.V., Zubkova N.A., Kalinchenko N.Yu., ... Malievskiy O.A., Orlova E.M., Petryaykina E.E., Samsonova L.N., Taranushenko T.E. Clinical guidelines "Precocious puberty". *Problemy Endocrinologii = Problems of Endocrinology*. 2021;67(5):84-103. doi 10.14341/probl12821 (in Russian)
- Roberts S.A., Kaiser U.B. Genetic etiologies of central precocious puberty and the role of imprinted genes. *Eur J Endocrinol.* 2020; 183(4):107-117. doi 10.1530/EJE-20-0103
- Sazhenova E.A., Vasilyev S.A., Rychkova L.V., Khramova E.E., Lebe-dev I.N. Genetics and epigenetics of precocious puberty. *Russ J Genet.* 2023;59(12):1277-1287. doi 10.1134/S1022795423120104
- Shim Y.S., Lee H.S., Hwang J.S. Genetic factors in precocious pu-berty. *Clin Exp Pediatr.* 2022;65(4):172-181. doi 10.3345/cep.2021.00521
- Tucci V., Isles A.R., Kelsey G., Ferguson-Smith A.C. Genomic imprint-ing and physiological processes in mammals. *Cell.* 2019;176(5): 952-965. doi 10.1016/j.cell.2019.01.043

Conflict of interest. The authors declare no conflict of interest.

Received October 15, 2024. Revised December 18, 2024. Accepted December 28, 2024.